Nektar Therapeutics (LON:0UNL)

Market Cap	632.60M
Revenue (ttm)	46.57M
Net Income (ttm)	-89.82M
Shares Out	n/a
EPS (ttm)	-5.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	705
Average Volume	5,091
Open	41.52
Previous Close	42.70
Day's Range	41.52 - 42.12
52-Week Range	12.00 - 66.68
Beta	0.58
RSI	32.44
Earnings Date	Feb 26, 2026

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1990
• Employees: 61
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0UNL

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Financial numbers in USD